Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer

Journal of Applied Physiology

Volumn 111, Issue 6, 2011, Pages 1687-1693

  Kossman, D A ^a   Williams, N I ^b   Domchek, S M ^c   Kurzer, M S ^d   Stopfer, J E ^c   Schmitz, K H ^e  

^a National Analysts Worldwide   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BRCA1 2 mutation carriers; Menstrual cycle

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; ARTICLE; BREAST TUMOR; EXERCISE; FEMALE; HUMAN; KINESIOTHERAPY; MENSTRUAL CYCLE; METHODOLOGY; MUTATION; PHYSIOLOGY; PREMENOPAUSE; RISK FACTOR; TUMOR SUPPRESSOR GENE; URINE;

ADULT; BREAST NEOPLASMS; ESTROGENS; EXERCISE; EXERCISE THERAPY; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MENSTRUAL CYCLE; MUTATION; PREMENOPAUSE; PROGESTERONE; RISK FACTORS;

EID: 83655165347     PISSN: 87507587     EISSN: 15221601     Source Type: Journal    
DOI: 10.1152/japplphysiol.00319.2011     Document Type: Article

References (69)

1. Aiello EJ, Tworoger SS, Yasui Y, Stanczyk FZ, Potter J, Ulrich CM, Irwin M, McTiernan A. Associations among circulating sex hormones, insulin-like growth factor, lipids, and mammographic density in postmenopausal women. Cancer Epidemiol Biomarkers Prev 14: 1411-1417, 2005. (Pubitemid 40807339)
2. Beitins IZ, McArthur JW, Turnbull BA, Skrinar GS, Bullen BA. Exercise induces two types of human luteal dysfunction: confirmation by urinary free progesterone. J Clin Endocrinol Metab 72: 1350-1358, 1991. (Pubitemid 21921853)
3. Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, Yaffe MJ. Mammographic density and the risk and detection of breast cancer. N Engl J Med 356: 227-236, 2007. (Pubitemid 46143226)
4. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J 85: 546-562, 1973.
5. Bullen BA, Skrinar GS, Beitins IZ, von Mering G, Turnbull BA, McArthur JW. Induction of menstrual disorders by strenuous exercise in untrained women. N Engl J Med 312: 1349-1353, 1985. (Pubitemid 15118296)
6. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer 73: 643-651, 1994. (Pubitemid 24046606)
7. Clemens M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 344: 276-285, 2001. (Pubitemid 32108534)
8. DeSouza MJ. Menstrual disturbances in athletes: a focus on luteal phase defects. Med Sci Sports Exerc 35: 1553-1563, 2003.
9. DeSouza MJ, Miller BE, Loucks AB, Luciano AA, Pescatello LS, Campbell CG, Lasley BL. High frequency of luteal phase deficiency and anovulation in recreational women runners: blunted elevation in folliclestimulating hormone observed during luteal-follicular transition. J Clin Endocrinol Metab 83: 4220-4232, 1998. (Pubitemid 29100113)
10. Domchek SM, Armstrong K, Weber BL. Clinical management of Brca1 and Brca2 mutation carriers. Nat Clin Pract Oncol 3: 2-3, 2006. (Pubitemid 43108824)
11. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Van t'veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304: 967-975, 2010.
12. Eccles DM. Hereditary cancer: guidelines in clinical practice. Breast and ovarian cancer. Genetics Ann Oncol 15, Suppl 4: iv133-138, 2004. (Pubitemid 39585325)
13. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 296: 193-201, 2006. (Pubitemid 44050373)
14. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98: 1406-1415, 2006. (Pubitemid 44530717)
15. Foster C, Jackson AS, Pollock ML, Taylor MM, Hare J, Sennett SM, Rod JL, Sarwar M, Schmidt DH. Generalized equations for predicting functional capacity from treadmill performance. Am Heart J 107: 1229-1234, 1984. (Pubitemid 14079663)
16. Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S, Linseisen J, Rohrmann S, Pischon T, Schulz M, Tjønneland A, Johnsen NF, Overvad K, Mendez M, Arguelles MV, Garcia CM, Larrañaga N, Chirlaque MD, Ardanaz E, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Dilis V, Trichopoulos D, Pala V, Palli D, Tumino R, Panico S, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Monninkhof E, Berglund G, Manjer J, Slimani N, Ferrari P, Kaaks R, Riboli E. Physical activity and the risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Int J Cancer 121: 347-355, 2007. (Pubitemid 46917704)
17. Genuth SM. The endocrine system. In: Physiology, edited by Berne RM, Levy MN. Philadelphia, PA: Mosby Year Book, 1993, p. 813-1024.
18. Goldenberger B, Lowenthal B, Darwin W, Cone E. Intrasubject variation of creatinine and specific gravity measurements in consecutive urine specimens of heroin users. Clin Chem 41: 1136-1147, 1995.
19. Guthrie RM, Lott JA, Kriesel S, Miller IL. Does the dipstick meet medical needs for urine specific gravity? J Fam Pract 25: 512-514, 1987. (Pubitemid 17166326)
20. Haddow JE, Knight GJ, Palomaki GE, Neveux LM, Chilmonczyk BA. Replacing creatinine measurements with specific gravity values to adjust urine creatinine concentrations. Clin Chem 40: 562-564, 1994. (Pubitemid 24116103)
21. Helzlsouer KJ, Alberg AJ, Bush TL, Longcope C, Gordon GB, Comstock GW. A prospective study of endogenous hormones and breast cancer. Cancer Detect Prev 18: 79-85, 1994. (Pubitemid 2077549)
22. Irwin ML, Aiello EJ, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R. Pre-diagnosis physical activity and mammographic density in breast cancer survivors. Breast Cancer Res Treat 95: 171-178, 2006.
23. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, O'Malley BW, Lydon JP. Progesterone involvement in breast development and tumorigenesis-as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 68: 779-787, 2003. (Pubitemid 37532400)
24. Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: a randomized trial. JAMA 282: 1554-1560, 1999. (Pubitemid 29504049)
25. Jeffery RW, Wing RR, Sherwood NE, Tate DF. Physical activity and weight loss: does prescribing higher physical activity goals improve outcome? Am J Clin Nutr 78: 684-689, 2003. (Pubitemid 39663485)
26. Johnsen NF, Tjønneland A, Thomsen BL, Christensen J, Loft S, Friedenreich C, Key TJ, Allen NE, Lahmann PH, Mejlvig L, Overvad K, Kaaks R, Rohrmann S, Boing H, Misirli G, Trichopoulou A, Zylis D, Tumino R, Pala V, Bueno-de-Mesquita HB, Kiemeney LA, Suárez LR, Gonzalez CA, Sánchez MJ, Huerta JM, Gurrea AB, Manjer J, Wirfält E, Khaw KT, Wareham N, Boffetta P, Egevad L, Rinaldi S, Riboli E. Physical activity and the risk of prostate cancer: the European prospective investigation into cancer and nutrition (EPIC) cohort. Int J Cancer 125: 902-908, 2009.
27. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, Palli D, Panico S, Peeters P, Quirós JR, Roddam A, Thiebaut A, Tjønneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European prospective investigation into cancer and nutrition (Epic). J Natl Cancer Inst 97: 755-765, 2005. (Pubitemid 40879595)
28. Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE. A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol Biomarkers Prev 9: 575-579, 2000. (Pubitemid 30396179)
29. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in Brca1 or Brca2. J Clin Oncol 25: 2921-2927, 2007. (Pubitemid 47123156)
30. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M, Nafa K, Offit K. Risk-reducing salpingo-oophorectomy in women with a Brca1 or Brca2 mutation. N Engl J Med 346: 1609-1615, 2002. (Pubitemid 34755668)
31. Kerlikowski K. The mammogram that cried wolf. N Engl J Med 356: 297-300, 2007.
32. King AC, Haskell WL, Taylor CB, Kraemer HC, DeBusk RF. Groupvs. home-based exercise training in healthy older men and women. A community-based clinical trial. JAMA 266: 1535-1542, 1991.
33. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in Brca1 and Brca2. Science 302: 643-646, 2003. (Pubitemid 37310920)
34. Kinsinger LS, Harris R, Woolf SH, Sox HC, Lohr KN. Chemoprevention of breast cancer: a summary of the evidence for the U.S Preventive Services Task Force. Ann Intern Med 137: 59-69, 2002.
35. Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P, Narod SA. Changes in body weight and the risk of breast cancer in Brca1 and Brca2 mutation carriers. Breast Cancer Res 7: R833-843, 2005.
36. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of Brca1 mutation carriers. J Clin Oncol 23: 8629-8635, 2005. (Pubitemid 46211505)
37. Lahmann PH, Norat T, Steindorf K, Boutron-Ruault MC, Pischon T, Mazuir M, Clavel-Chapelon F, Linseisen J, Boeing H, Bergman M, Johnsen NF, Tjønneland A, Overvad K, Mendez M, Quirós JR, Martinez C, Dorronsoro M, Navarro C, Gurrea AB, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Trichopoulos D, Orfanou N, Krogh V, Palli D, Tumino R, Panico S, Vineis P, Bueno-deMesquita HB, Peeters PH, Monninkhof E, Berglund G, Manjer J, Ferrari P, Slimani N, Kaaks R, Riboli E. Physical activity and risk of colon and rectal cancers: the European prospective investigation in to cancer and nutrition. Cancer Epidemiol Biomarkers Prev 15: 2398-2407, 2006. (Pubitemid 46048296)
38. Lahmann PH, Friedenreich C, Schuit AJ, Salvini S, Allen NE, Key TJ, Khaw KT, Bingham S, Peeters PH, Monninkhof E, Bueno-de-Mesquita HB, Wirfält E, Manjer J, Gonzales CA, Ardanaz E, Amiano P, Quirós JR, Navarro C, Martinez C, Berrino F, Palli D, Tumino R, Panico S, Vineis P, Trichopoulou A, Bamia C, Trichopoulos D, Boeing H, Schulz M, Linseisen J, Chang-Claude J, Chapelon FC, Fournier A, Boutron-Ruault MC, Tjønneland A, Føns Johnson N, Overvad K, Kaaks R, Riboli E. Physical activity and breast cancer risk: the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 16: 36-42, 2007. (Pubitemid 46174261)
39. Lahmann PH, Friedenreich C, Schulz M, Cust AE, Lukanova A, Kaaks R, Tjønneland A, Johnsen NF, Overvad K, Fournier A, Boutron-Ruault MC, Clavel Chapelon F, Boeing H, Linseisen J, Rohrmann S, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Mattiello A, Sacerdote C, Agnoli C, Tumino R, Quirós JR, Larrañaga N, Agudo AT, Sánchez MJ, Berglund G, Manjer J, Monninkhof EM, Peeters PH, Bueno-de-Mesquita HB, May AM, Allen N, Khaw KT, Bingham S, Rinaldi S, Ferrari P, Riboli E. Physical activity and ovarian cancer risk: the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 18: 351-354, 2009.
40. Loucks AB. Energy availability, not body fatness, regulates reproductive function in women. Exerc Sport Sci Rev 31: 144-148, 2003. (Pubitemid 36886028)
41. Loucks AB, Thuma JR. Luteinizing hormone pulsatility is disrupted at a threshold of energy availability in regularly menstruating women. J Clin Endocrinol Metab 88: 297-311, 2003. (Pubitemid 36115181)
42. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azavedo E, Söderqvist G, Mol-Arts M, Barkfeldt J, von Schoultz B. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 186: 717-722, 2002. (Pubitemid 34494352)
43. Maruti SS, Willett WC, Feskanich D, Rosner B, Colditz GA. A prospective study of age-specific physical activity and premenopausal breast cancer. J Natl Cancer Inst 100: 728-737, 2008.
44. Medina D. Mammary developmental fate and breast cancer risk. Endocr Relat Cancer 12: 483-495, 2005. (Pubitemid 41482989)
45. Metcalfe KA, Goel V, Lickley L, Semple J, Narod SA. Prophylactic bilateral mastectomy: patterns of practice. Cancer 95: 236-242, 2002. (Pubitemid 34787587)
46. Michaud DS, Manson JE, Spiegelman D, Barbieri RL, Sepkovic DW, Bradlow HL, Hankinson SE. Reproducibility of plasma and urinary sex hormone levels in premenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 8: 1059-1064, 1999. (Pubitemid 30004902)
47. Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, Sieri S, Pala V, Berrino F. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 112: 312-318, 2004. (Pubitemid 39244371)
48. Munro C, Stbenfeldt G, Cragun J, Addiego LA, Overstreet JW, Lasley BL. Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their majority urinary metabolites as measured by enzyme immunoassay and radioassay. Clin Chem 37: 838-844, 1991. (Pubitemid 21925926)
49. Muti P, Trevisan M, Micheli A, Krogh V, Bolelli G, Sciajno R, Berrino F. Reliability of serum hormones in premenopausal and postmenopausal women over a one-year period. Cancer Epidemiol Biomarkers Prev 5: 917-922, 1996. (Pubitemid 26382987)
50. Narod SA. Modifiers of risk of hereditary breast cancer. Oncogene 25: 5832-5836, 2006. (Pubitemid 44453438)
51. O'Connor KA, Brindle E, Holman DJ, Klein NA, Soules MR, Campbell KL, Kohen F, Munro CJ, Shofer JB, Lasley BL, Wood JW. Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research. Clin Chem 49: 1139-1148, 2003. (Pubitemid 36751101)
52. O'Dougherty M, Dallman A, Turcotte L, Patterson J, Napolitano MA, Schmitz KH. Barriers and motivators for strength training among women of color and Caucasian women. Women Health 47: 41-62, 2008.
53. Pettersson K, Alfthan H, Stenman UH, Turpeinen U, Suonpää M, Söderholm J, Larsen SO, Nørgaard-Pedersen B. Simultaneous assay of alpha-fetoprotein and free beta subunit of human chorionic gonadotropin by dual-label time-resolved immunofluorometric assay. Clin Chem 39: 2084-2089, 1993. (Pubitemid 23306155)
54. Rebbeck TR. Prophylactic oophorectomy in Brca 1 and Brca2 mutation carriers. Eur J Cancer 38, Suppl 6: S15-7, 2002. (Pubitemid 35284376)
55. Rosenberg CR, Pasternack BS, Shore RE, Koenig KL, Toniolo PG. Premenopausal estradiol levels and the risk of breast cancer: a new method of controlling for day of the menstrual cycle. Am J Epidemiol 140: 518-525, 1994. (Pubitemid 24285934)
56. Sherwood NE, Jeffery RW. The behavioral determinants of exercise: implications for physical activity interventions. Annu Rev Nutr 20: 21-44, 2000.
57. Siri WE. The gross composition of the body. Adv Biol Med Physics 4: 239-280, 1956.
58. Steindorf K, Friedenreich C, Linseisen J, Rohrmann S, Rundle A, Veglia F, Vineis P, Johnsen NF, Tjønneland A, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Schulz M, Boeing H, Trichopoulou A, Kalapothaki V, Koliva M, Krogh V, Palli D, Tumino R, Panico S, Monninkhof E, Peeters PH, Boshuizen HC, Bueno-de-Mesquita HB, Chirlaque MD, Agudo A, Larrañaga N, Quirós JR, Martínez C, Barricarte A, Janzon L, Berglund G, Bingham S, Khaw KT, Key TJ, Norat T, Jenab M, Cust A, Riboli E. Physical activity and lung cancer risk: the European prospective investigation into cancer and nutrition cohort. Int J Cancer 119: 2387-2397, 2006.
59. Thomas H, Key T, Allen D, Moore JW, Dowsett M, Fentiman IS, Wang DY. Re: reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst 89: 396-398, 1997.
60. Thune I, Brenn T, Lund E, Gaard M. Physical activity and the risk of breast cancer. N Engl J Med 336: 1269-1275, 1997. (Pubitemid 27187779)
61. Toniolo P, Koenig KL, Pasternack BS. et al Reliability of measurements of total, protein-bound, and unbound estradiol in serum. Cancer Epidemiol Biomarkers Prev 3: 47-50, 1994. (Pubitemid 24172521)
62. Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B. Association between clinical characteristics and risk-reduction interventions in women who underwent Brca1 and Brca2 testing: a single-institution study. Cancer 107: 2745-2751, 2006. (Pubitemid 44937026)
63. Wainberg S, Husted J. Utilization of screening and preventive surgery among unaffected carriers of a Brca1 or Brca2 gene mutation. Cancer Epidemiol Biomarkers Prev 13: 1989-1995, 2004.
64. Williams NI. Lessons from experimental disruptions of the menstrual cycle in humans and monkeys. Med Sci Sports Exerc 35: 1564-1572, 2003. (Pubitemid 37087588)
65. Williams NI, Caston-Balderrama AL, Helmreich DL, Parfitt DB, Nosbisch C, Cameron JL. Longitudinal changes in reproductive hormones and menstrual cyclicity in cynomolgus monkeys during strenuous exercise training: abrupt transition to exercise-induced amenorrhea. Endocrinology 2: 2381-2389, 2001. (Pubitemid 32473093)
66. Williams NI, Helmreich DL, Parfitt DB, Caston-Balderrama A, Cameron JL. Evidence for a causal role of low energy availability in the induction of menstrual cycle disturbances during strenuous exercise training. J Clin Endocrinol Metab 86: 5184-5193, 2001. (Pubitemid 33070234)
67. Winters KM, Adams WC, Meredith CN, Loan MD, Lasley BL. Density and cyclic ovarian function in trained runners and active controls. Med Sci Sports Exerc 28: 776-78, 1996.
68. Wysowski DK, Comstock GW, Helsing KJ, Lau HL. Sex hormone levels in serum in relation to the development of breast cancer. Am J Epidemiol 125: 791-799, 1987. (Pubitemid 17066478)
69. Yue W, Santen R, Wang J, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem 86: 477-86, 2003. (Pubitemid 37412587)